Background and Objective: Hyperthyroidism is a common clinical disorder all over world. It occurs at all ages, but is less common before the age of 15 and is an important cause of morbidity in the older age group. Hyperthyroidism is ten times more common in women than men and has a prevalence of 2.5-4.7 per 1000 women. Hyperthyroidism is affecting approximately 2 percent of women and 0.2 percent of men. Even though diagnosis in hyperthyroidism is generally straight forward, its prevalence varies among population.

Methods: Study included 75 patients attending outpatient department (OPD)/admitted in tertiary care Hospital fulfilling the inclusion and exclusion criteria.

Results: Study include 75 patients of hyperthyroidism in which 61 were females and 14 were male patients with female to male ratio of approximately 4.35:1. Incidence of hyperthyroidism is common in the age group between 31 to 40 years. Graves’ disease (76%) was the most common cause of hyperthyroidism, followed by toxic multinodular goiter (18.7%) and toxic adenoma (5.3%). Majority (54.7%) of the patients presented within 12 months of symptom onset. The common clinical manifestations were nervousness (94.7%), increased sweating, heat intolerance and swelling in the neck (90.7%). The commonest signs were goiter (100%), warm skin (90.7%) and tremors (92%).  49.3% of the patients had sinus tachycardia and 9.3% of patients had atrial fibrillation.

Conclusion: Hyperthyroidism was common in the third decade and in females. Graves’ disease was the most common cause of hyperthyroidism. Commonest clinical manifestations were nervousness, increased sweating, heat intolerance and swelling in the neck. Commonest signs were goiter, warm skin and tremors.

Keywords: Hyperthyroidism, Graves’ disease, toxic multinodular goiter, Toxic adenoma.

1. David S Cooper. Hyperthyroidism. The Lancet 2003; 362:459-68.
2. John H Lazarus. Hyperthyroidism. The Lancet 1997; 349:339-43.
3. Tunbridge WM, Evered DC, et al. Spectrum of Thyroid Disease in the community, Whickham Survey; Clin Endocrinol (oxf) 1977; 7:481-93.
4. Jameson JL, Weetman AP. Disorders of Thyroid gland; In: Kasper, Fauci, Braunwald, Hauser, Jamson eds: Harrison’s Principles of Internal Medicine, 16th edition, Vol-2, New Delhi; McGraw Hill; 2005: 2104-2127.
5. Sidney C Werner, Ingbar SH (eds). Introduction of hyperthyroidism. The Thyroid: 3rd edition, 491-502.
6. Zargar AH, Bashir MI,  Wani AI, et al. clinical and endocrine aspects of thyrotoxicosis and its cardiovascular complications. Annals of Saudi Medicine 2000; 20(5-6): 485-7.
7. Michael M Kaplan.   Endo Clin N America 1998; 27:1-6.
8. Joll AC. Diseases of the Thyroid Gland. 2^nd edition, New York, Grune and Stratton 1951.
9. Spaulding SW and Utiger R. In Felig P and Frdiman L (eds). Endocrinology and Metabolism. New York; McGraw Hill; 1981:308.
10. Williams RH et al. Thiouracil treatment of thyrotoxicosis. J Clin Endocrnol 1946; 6:1-22.
11. Terry F. Davies and P.Reed Larson; Thyrotoxicosis; In: Larsen, Kronenberg, Melmed, Polonsky eds: Williams Text Book of Endocrinology, 10^th edition, Saunders 2003: 374-421.
12. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentration as a risk factor for atrial fibrillation in older persons.  N Engl J Med 1994; 331:1249-125.

Dr Shankarappa R S

Email: sushishyla @rediffmail.com